Prospect Venture Partners is a leading life sciences venture capital firm dedicated to building outstanding biomedical companies. With more than $1B of capital raised, Prospect Ventures supports innovative companies from seed to growth stage. We seek to partner with exceptional teams committed to excellence.
Prospect Ventures management team:
Managing Director, Russell Hirsch
Managing Director, David Schnell
CFO, Lisa Potocsnak
https://www.prospectventurepartners.com/partners/
Prospect Ventures management team:
Managing Director, Russell Hirsch
Managing Director, David Schnell
CFO, Lisa Potocsnak
https://www.prospectventurepartners.com/partners/
Location: United States, California, Palo Alto
Employees: 1-10
Founded date: 1997
Investment Type: Venture Capital
Portfolio 18
| Date | Name | Website | Total Raised | Location |
| - | investor.jnj.com | - | - | |
| - | Nanosys | nanosysinc.com | $60M | United Sta... |
| - | Senomyx, I... | senomyx.com | - | - |
| - | PharmaTime... | pharmatimes.com | - | United Kin... |
| - | Novavax | novavax.com | - | United Sta... |
| - | Infinity P... | infi.com | - | United Sta... |
| - | Fierce Bio... | fiercebiotech.com | - | United Sta... |
| - | Ninepoint ... | ninepointmedical.com | $67M | United Sta... |
| - | SentreHEAR... | sentreheart.com | $61M | - |
| - | The Wall S... | wsj.com | - | United Sta... |
Show more
News 68
Show more
Mentions in press and media 17
| Date | Title | Description |
| 08.11.2011 | DFINE Closes $25M Equity Financing | DFINE, Inc., a San Jose, CA-based developer of minimally invasive radiofrequency (RF) targeted therapies for the treatment of vertebral pathologies, has closed a $25m equity financing. Backers incluse existing investors OrbiMed Advisors, Pr... |
| 18.10.2011 | TOPICA Pharmaceuticals Raises $27M in Series B Funding | TOPICA Pharmaceuticals, Inc., a Palo Alto, CA-based clinical research stage pharmaceutical company, has raised $27m in a Series B funding. Backers include Third Rock Ventures and existing investors Prospect Venture Partners and Yasuda Enter... |
| 24.08.2009 | Complete Genomics seals $45M for cheaper gene sequencing | Complete Genomics, provider of supposedly cheaper and faster DNA sequencing services, has raised $45 million in a fourth round of funding — a huge amount for a biotech company in today’s economic environment. Based in Mountain View, Calif.,... |
| 24.08.2009 | Complete Genomics seals $45M for cheaper gene sequencing | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today! Complete Genomics, provider of supposedly cheaper... |
| 04.02.2009 | Allux Medical shuts down, turns to Sherwood | Silicon Valley shutdown/turnaround consultancy Sherwood Partners has been called in by ailing Allux Medical, a Menlo Park, Calif.-based developer of devices used to treat airway and skin inflammatory diseases. The company, which managed to ... |
| 28.01.2009 | Cardiovascular drug developer Cogentus files for Chapter 7 | Menlo Park, Calif.-based Cogentus Pharmaceuticals has filed for Chapter 7 bankruptcy, despite $83 million raised in equity capital. At the time of the filing, the company reported $2.2 million in assets and liabilities totaling $17.2 millio... |
| 08.01.2009 | Satori brings in $22M to stop Alzheimer’s in its tracks | Satori Pharmaceuticals, a company that says it’s developing drugs with the potential to actually stop Alzheimer’s disease in its early phases — an unprecedented claim — landed $22 million in second-round funding to push its products through... |
| 05.01.2009 | DFine secures $35M to treat spinal fractures | Medical device maker DFine brought in $35 million in fourth round funding to develop and market its StabiliT Vertebral Augmentation System, a device that injects bone cement to heal fissures in patients’ spinal columns. The original target ... |
| 29.10.2008 | DFine stacks up $30M to mend spinal fractures | Healthcare developer DFine has brought in $30 million in fourth-round funding to commercialize a system to treat fractures in vertebrae caused by spine compression. Contributions came from BB&T Funds, Highland Capital Management, Prospe... |
| 23.10.2008 | Nora Pharma reels in $25M for women’s health | Nora Pharmaceuticals, developer of women’s reproductive health drugs and devices, brought in $25 million in first round financing from Burrill & Co., Prospect Venture Partners and Vivo Ventures. The San Francisco-based company is still ... |
Show more